- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
No ibuprofen for COVID-19 patients says WHO
Ibuprofen's anti-inflammatory properties could "dampen down" the immune system, which could slow the recovery process.
Geneva: Novel COVID-19 caused by SARS-CoV 2 virus which was first reported in December 2019 first observed in Wuhan, China, now has become a pandemic condition affecting about 166 countries. The condition has infected around 190,000 people worldwide and killed more than 7,800, with mild symptoms in most people, but can result in pneumonia and in some cases severe illness that can lead...
Geneva: Novel COVID-19 caused by SARS-CoV 2 virus which was first reported in December 2019 first observed in Wuhan, China, now has become a pandemic condition affecting about 166 countries. The condition has infected around 190,000 people worldwide and killed more than 7,800, with mild symptoms in most people, but can result in pneumonia and in some cases severe illness that can lead to multiple organ failure.
The World Health Organisation recommended that people suffering from Covid-19 symptoms avoid taking ibuprofen after French officials warned that anti-inflammatory drugs could worsen the effects of the virus. The minister, Oliver Veran, tweeted on Saturday 14 March that people with suspected COVID-19 should avoid anti-inflammatory drugs. "Taking anti-inflammatory drugs (ibuprofen, cortisone . . .) could be an aggravating factor for the infection. If you have a fever, take paracetamol," he stated.
The warning by French Health Minister Veran followed a recent study published in the British Medical Journal hypothesized that an enzyme boosted by anti-inflammatory drugs such as ibuprofen could facilitate and worsen COVID-19 infections.
Paul Little, a professor of primary care research at the University of Southampton, had stated that there was good evidence "that prolonged illness or the complications of respiratory infections may be more common when NSAIDs are used—both respiratory or septic complications and cardiovascular complications."
Ian Jones, a professor of virology at the University of Reading, had stated that ibuprofen's anti-inflammatory properties could "dampen down" the immune system, which could slow the recovery process. He added that it was likely, based on similarities between the new virus (SARS-CoV-2) and SARS I, that COVID-19 reduces a key enzyme that part regulates the water and salt concentration in the blood and could contribute to pneumonia seen in extreme cases. Ibuprofen aggravates this, while paracetamol does not.
"We do not currently believe there is any proven scientific evidence linking over-the-counter use of ibuprofen to the aggravation of COVID-19," concluded the authors.
For further reading click on the following link,
MBBS
Dr K B AARTHI-has completed MBBS from SRM UNIVERSITY TAMIL NADU,Her interest is in the field of Pediatrics and Anaesthesia, also passionate in doing research and publishing articles.She joined Medical Dialogues in 2020 and publishes health news and medical updates. Email: editorial@medicaldialogues.in. Contact no. 011-43720751,9786713226
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: editorial@medicaldialogues.in. Contact no. 011-43720751